The Putative S1PR1 Modulator ACT-209905 Impairs Growth and Migration of Glioblastoma Cells In Vitro

Area of Science:

• Neuro-oncology
• Molecular biology
• Cancer research

Background:

• Glioblastoma (GBM) remains a lethal brain tumor due to its invasive nature and therapeutic resistance.
• Sphingosine-1-phosphate (S1P) signaling, particularly through its receptor S1PR1, is increasingly recognized for its role in promoting tumor growth.

Purpose of the Study:

• To investigate the therapeutic potential of ACT-209905, a novel S1PR1 modulator, against glioblastoma.
• To elucidate the mechanisms by which S1PR1 signaling influences GBM cell behavior and interacts with monocytic cells.

Main Methods:

• Assessed the effects of ACT-209905 on the viability and migration of human (LN-18) and murine (GL261) GBM cells.
• Utilized co-culture systems with monocytic THP-1 cells and conditioned media to mimic the tumor microenvironment.
• Performed immunoblot analyses to evaluate kinase activation (p38, AKT1, ERK1/2) and flow cytometry to assess cell surface marker expression (CD62P, ICAM-1, P-Selectin).

Main Results:

• ACT-209905 significantly inhibited GBM cell viability and migration.
• Co-culture with THP-1 cells or conditioned medium enhanced GBM cell growth and migration, effects that were reversed by ACT-209905.
• ACT-209905 reduced pro-growth kinase activation and the expression of pro-migratory markers, while counteracting THP-1-induced increases in ICAM-1 and P-Selectin.

Conclusions:

• S1PR1 signaling plays a critical role in driving glioblastoma cell proliferation and invasion.
• ACT-209905 demonstrates significant anti-tumor activity against GBM, both independently and in the context of monocytic cell interaction.
• The findings provide a mechanistic basis for the pro-tumorigenic influence of macrophages on GBM and highlight S1PR1 as a promising therapeutic target.